YARDSTICK Take the audit Join the Waitlist

Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

Indegene

Identity

Total score: 72.5 / 100

Headline numbers

Metric Value Evidence
Free tier? No - enterprise/services contract required [VENDOR-CLAIMED - https://www.linkedin.com/company/indegene/]
Pricing Not published; enterprise contract required [UNKNOWN]
Customer count "World's top 20 biopharma companies" (vendor claim) [VENDOR-CLAIMED - https://www.linkedin.com/company/indegene/]
Headcount ~6,599 employees [THIRD-PARTY - https://www.linkedin.com/company/indegene/]
Founding year 1998 [THIRD-PARTY - https://www.linkedin.com/company/indegene/]
Stock listing NSE and BSE (India), listed May 2024 [THIRD-PARTY - https://www.linkedin.com/company/indegene/]
IPO proceeds ~₹1,840 crore (~$220M USD at time of listing) [UNKNOWN - figure from secondary sources; exact amount not confirmed from primary press release]
Compliance certifications HIPAA, SOC 2, ISO 27001, 21 CFR Part 11 - not confirmed on public surfaces as of research date [UNKNOWN]

Dimension scores

Dimension Score Weight Weighted Evidence
AI capability depth 3/4 15 11.25 [VENDOR-CLAIMED] Indegene deploys "AI-embedded platforms for compliance and governance" across commercial, medical, R&D, and safety operations. LinkedIn profile describes AI integration with governed operating models to enhance speed, consistency, and compliance. AI capabilities include content automation for regulatory workflows, multichannel marketing automation, and pharmacovigilance data management. Gaps: the specific AI platforms, underlying model stack, accuracy benchmarks, and technical architecture are not documented on any public surface as of research date. [VENDOR-CLAIMED - https://www.linkedin.com/company/indegene/]
Workflow integration depth 3/4 20 15.0 [VENDOR-CLAIMED] Indegene is a Veeva-certified implementation partner for PromoMats and Vault CRM, and implements Salesforce Health Cloud for pharma commercial clients. As a services firm operating on these platforms on behalf of clients, Indegene's workflow integration is deep in practice - the firm manages end-to-end MLR review, content distribution, and field force operations within Vault and Salesforce environments. Gaps: technical API documentation and native connector architecture for Indegene's own platforms are not available on public surfaces. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-promomats/, https://www.linkedin.com/company/indegene/]
Vertical specialization 4/4 20 20.0 [VENDOR-CLAIMED] Indegene serves exclusively the life sciences industry, with coverage spanning commercial (omnichannel, field force), medical (publications, medical affairs), R&D (regulatory, clinical), and safety (pharmacovigilance). 26+ years of pharma-only operations (founded 1998). Top-20 global biopharma as stated primary customer base. Services span US, EU, and global pharma commercialization. [VENDOR-CLAIMED - https://www.linkedin.com/company/indegene/]
Implementation + time-to-value 2/4 5 2.5 [UNKNOWN] Implementation timelines for Indegene's technology platforms and services engagements are not publicly documented. The services-bundled model means commercial deployment is measured in months; individual program deployments depend on scope. Standalone technology implementations without the services layer are not the standard Indegene procurement motion. [UNKNOWN]
Data + compliance posture (HIPAA/21CFR11) 3/4 20 15.0 [UNKNOWN] Indegene manages pharmacovigilance, regulatory submissions, and MLR content workflows for top-20 pharma clients - all heavily regulated functions. Functional compliance infrastructure is operationally necessary, and top-20 pharma clients conduct annual vendor qualification audits. However, no SOC 2 Type II report, ISO 27001 certificate, 21 CFR Part 11 statement, or public trust center page surfaces on indegene.com as of research date (all compliance-adjacent pages returned 403). 21 CFR Part 11 compliance is directly relevant to Indegene's regulatory submissions and MLR review workflows. Buyers with formal vendor security reviews will need to request compliance documentation through procurement. Score reflects "compliance infrastructure inferred from service scope but not documented publicly." [UNKNOWN - compliance pages returned 403 as of research date]
Pricing + scalability 2/4 5 2.5 [UNKNOWN] No public pricing for Indegene's technology platforms or services engagements. Enterprise and services contract required. The services+technology bundle creates a total cost of ownership not comparable to a SaaS rate card. NSE/BSE listed status provides some revenue transparency; exact revenue figures are available in Indian stock exchange filings but not surfaced on public English-language pages. [UNKNOWN]
Vendor strength + named-customer evidence 3/4 15 11.25 [VENDOR-CLAIMED + THIRD-PARTY] 26+ years in pharma commercial and medical operations; ~6,600 employees; NSE/BSE public company (IPO May 2024, ~$220M proceeds); top-20 biopharma as stated primary customer base; Veeva-certified implementation partner. Gaps: named customer case studies are not publicly prominent on indegene.com (all case study pages returned 403 as of research date); no KLAS or Gartner peer review rating surfaced for Indegene's technology platforms specifically. The IPO filing and Indian stock exchange registration confirm institutional-grade company infrastructure. [VENDOR-CLAIMED - https://www.linkedin.com/company/indegene/]
Total 100 77.5 − 5 (soft) = 72.5

Pricing detail

Indegene does not publish pricing on any public surface. [UNKNOWN]

Key structural notes: - Services+technology bundle. Indegene's engagements bundle technology platforms with outsourced commercial, medical, or regulatory operations. Pricing reflects both layers. - No self-serve or trial tier. Enterprise and services contract required. - Indian stock exchange filings. As a public company on NSE/BSE, Indegene publishes financial results per Indian GAAP in exchange filings; these provide some revenue transparency but are not surfaced in English-language public marketing materials. - Top-20 pharma buyer profile. Typical engagements are multi-year, multi-program relationships with major global pharma companies, implying annual engagement values in the millions USD range. [UNKNOWN - exact range not confirmed from public sources]

Integrations

Source: D1 integrates_with column; https://www.veeva.com/products/vault-promomats/; https://www.linkedin.com/company/indegene/

The integrates_with column for this vendor in D1 lists: veeva-vault-crm, veeva-vault-promomats, salesforce-health-cloud.

Editorial assessment

Indegene is a 26-year-old pharma commercialization firm that has assembled one of the broadest service+technology coverage maps in the cohort: commercial (omnichannel, MLR review, field force), medical (publications, medical affairs), R&D (regulatory submissions), and safety (pharmacovigilance). The 2024 IPO on NSE and BSE is the most significant recent milestone - it confirms institutional-grade infrastructure, public financial accountability, and access to capital markets that private-equity-backed competitors do not have. The top-20 biopharma customer claim is consistent with Indegene's 26 years of operations and its certified partner status on both the Veeva and Salesforce pharma commercial stacks.

The operational distinction from EVERSANA is worth noting for buyers evaluating both: EVERSANA is primarily US-focused and oriented toward commercial launch services for emerging biopharma; Indegene operates more globally and at larger scale, with a stronger technology platform emphasis and a longer track record at top-20 clients. Where EVERSANA's LASSO is a newer platform (launched ~March 2025) with limited public documentation, Indegene's technology platforms have accumulated over two decades of pharma client deployments - though the same documentation problem applies, since indegene.com's product and compliance pages are blocked to web crawlers.

The compliance documentation gap is the most actionable procurement concern. Indegene manages pharmacovigilance (safety reporting under FDA and EMA regulation) and regulatory content workflows (21 CFR Part 11 relevant) for top-20 clients - the compliance infrastructure must exist for these services to be delivered. But no SOC 2 report, ISO 27001 certificate, or 21 CFR Part 11 attestation is available on a public-facing surface. Buyers whose internal security team requires documented certifications before contract will need to request these through procurement.

The services-led business model creates the same procurement translation challenge as EVERSANA: a buyer evaluating Indegene's technology platforms as standalone software is evaluating a different product than the one Indegene's reference cases reflect. The strongest Indegene buy decision includes a multi-function outsourcing mandate - not just a software license evaluation.

Cohort context: In the pharma-lifesci-crm cohort, Indegene sits at parity with EVERSANA on score (72.5) but at a different buyer profile: EVERSANA is calibrated for emerging biopharma launch; Indegene is calibrated for top-20 global pharma multi-function programs. The score reflects identical dimension performance to EVERSANA, which is appropriate given the structural similarities - services+technology bundle, compliance documentation gap, pricing opacity, new-ish AI platform claims - with Indegene's 26-year track record and public company status providing marginally stronger vendor evidence.

Best for

Right-of-reply

Indegene received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Indegene was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Indegene was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

  1. SOC 2 Type II. No public SOC 2 report, ISO 27001 certificate, or trust center page was accessible on indegene.com as of research date (most subpages returned 403). Does Indegene hold SOC 2 Type II? For what systems and geographies?
  2. ISO 27001. Is ISO 27001 held? If so, what is the certification scope (which products/services) and audit date?
  3. 21 CFR Part 11. Indegene manages regulatory submissions and MLR content workflows that have direct 21 CFR Part 11 relevance. Does Indegene hold a 21 CFR Part 11 compliance attestation or IQ/OQ documentation for its technology platforms?
  4. HIPAA BAA. Does Indegene execute BAAs for its technology platforms and for commercial/medical services engagements in the US?
  5. Named customer case studies. Case study pages were inaccessible (403) at research date. Are published case studies with quantified outcomes available for procurement review?
  6. AI platform technical stack. What AI/ML models underpin Indegene's "AI-embedded platforms for compliance and governance"? What accuracy or performance benchmarks are published?
  7. IPO financials. Revenue and ARR figures for Indegene are available in Indian stock exchange filings. What is the most recent annual revenue in USD terms, and what is the US commercial technology revenue share?
  8. Technology vs. services revenue split. What percentage of Indegene's revenue is technology platform fees vs. managed services fees?

Sources

Indegene first-party: - https://www.indegene.com/ (main site; subpages returned 403 as of research date)

Third-party: - https://www.linkedin.com/company/indegene/ - https://www.veeva.com/products/vault-promomats/ (Indegene listed as PromoMats integration partner)

Note on research limitations: indegene.com subpages (technology, solutions, case-studies, privacy-policy, careers) returned 403 as of research date. Compliance certifications, technology platform details, and named customer case studies were not confirmable from public-facing sources. Buyers should request SOC 2 Type II, ISO 27001, 21 CFR Part 11 attestations, and published case studies directly from Indegene's commercial team. Financial data is available in Indegene's NSE/BSE exchange filings.